Clinical Trial

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Study acronym: (HCC)
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-01-17; most recent amendment 2025-10-02.
Status change: Not Yet Recruiting → Recruiting 2025-02-25
Trial Details
NCT Number NCT06789757
Lead Sponsor Inova Health Care Services
Conditions Hepatocellular Carcinoma
Enrollment 19 participants
Start Date 2025-02-25
Primary Completion 2026-10-27 (estimated)
Study Completion 2028-01-27 (estimated)
Updated on ClinicalTrials.gov 2025-10-07